In some cases these drugs bind primary oncogenic drivers such as ErbB2, which is overexpressed in the HER2amp breast cancer subtype [3], or ErbB1, which is mutated in non-small cell lung cancer [4]. Here, ERBB2 is linked to breast carcinoma.